K
v
ire
.com
←
Back
Night
Docs
Library
Review
…
Author
Robert J. Motzer
also known as Motzer, R.J., Motzer, Robert, Motzer, Robert J
Memorial Sloan Kettering Cancer Center · Cornell University · Kettering University · Privolzhsky Research Medical University
About this author
Works
1,588
Cited by
123,648
h-index
148
i10
699
ORCID ↗
Top papers
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer, Bernard Escudier, Ray McDermott, et al.
·
2015
·
New England Journal of Medicine
↗ 5,855
OA
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, et al.
·
2007
·
New England Journal of Medicine
↗ 5,740
OA
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Robert J. Motzer, Nizar M. Tannir, Ray McDermott, et al.
·
2018
·
New England Journal of Medicine
↗ 4,577
OA
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert Samstein, Chung‐Han Lee, Alexander N. Shoushtari, et al.
·
2019
·
Nature Genetics
↗ 4,323
OA
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Gary R. Hudes, Michael A. Carducci, Piotr Tomczak, et al.
·
2007
·
New England Journal of Medicine
↗ 3,645
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer, Bernard Escudier, Stéphane Oudard, et al.
·
2008
·
The Lancet
↗ 3,004
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Robert J. Motzer, Konstantin Penkov, John B.A.G. Haanen, et al.
·
2019
·
New England Journal of Medicine
↗ 2,516
OA
Renal-Cell Carcinoma
Robert J. Motzer, Neil H. Bander, David M. Nanus
·
1996
·
New England Journal of Medicine
↗ 2,244
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, et al.
·
2009
·
Journal of Clinical Oncology
↗ 2,187
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Robert J. Motzer, Thomas E. Hutson, David Cella, et al.
·
2013
·
New England Journal of Medicine
↗ 1,905
OA
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Brian I. Rini, Bernard Escudier, Piotr Tomczak, et al.
·
2011
·
The Lancet
↗ 1,840
Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
Robert J. Motzer, Madhu Mazumdar, Jennifer Bacik, et al.
·
1999
·
Journal of Clinical Oncology
↗ 1,801